E. Ohman J:or Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

E. Ohman J:or Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.38M	Hold	8,823	–	–	0.1%	106
2026 Q1	$3.94M	Sell	8,823 -200	-2%	-$93.3K	0.1%	109
2025 Q4	$4.09M	Sell	9,023 -1,497	-14%	-$645K	0.1%	107
2025 Q3	$4.12M	Hold	10,520	–	–	0.1%	102
2025 Q2	$4.68M	Sell	10,520 -970	-8%	-$447K	0.12%	93
2025 Q1	$5.57M	Sell	11,490 -250	-2%	-$117K	0.15%	83
2024 Q4	$4.73M	Buy	11,740 +1,430	+14%	+$663K	0.11%	96
2024 Q3	$4.79M	Sell	10,310 -750	-7%	-$360K	0.12%	86
2024 Q2	$5.18M	Buy	11,060 +560	+5%	+$243K	0.13%	89
2024 Q1	$4.39M	Buy	10,500 +500	+5%	+$211K	0.11%	96
2023 Q4	$4.07M	Sell	10,000 -1,900	-16%	-$702K	0.15%	83
2023 Q3	$4.14M	Buy	+11,900	New	+$4.16M	0.16%	85
2022 Q3	–	Sell	-11,100	Closed	-$3.13M	–	450
2022 Q2	$3.13M	Sell	11,100 -200	-2%	-$53.5K	0.14%	96
2022 Q1	$2.95M	Sell	11,300 -1,500	-12%	-$356K	0.1%	117
2021 Q4	$2.81M	Buy	12,800 +900	+8%	+$175K	0.08%	152
2021 Q3	$2.16M	Hold	11,900	–	–	0.07%	166
2021 Q2	$2.4M	Sell	11,900 -162,150	-93%	-$33.9M	0.08%	157
2021 Q1	$37.4M	Buy	174,050 +163,250	+1,512%	+$35.9M	1.35%	19
2020 Q4	$2.55M	Hold	10,800	–	–	0.1%	116
2020 Q3	$2.94M	Buy	10,800 +800	+8%	+$221K	0.15%	87
2020 Q2	$2.9M	Buy	10,000 +1,100	+12%	+$298K	0.17%	85
2020 Q1	$2.12M	Sell	8,900 -3,400	-28%	-$780K	0.16%	83
2019 Q4	$2.69M	Buy	+12,300	New	+$2.49M	0.15%	90
2018 Q2	–	Sell	-5,900	Closed	-$962K	–	523
2018 Q1	$962K	Sell	5,900 -600	-9%	-$98K	0.08%	160
2017 Q4	$974K	Hold	6,500	–	–	0.08%	157
2017 Q3	$988K	Buy	6,500 +200	+3%	+$30.1K	0.09%	151
2017 Q2	$812K	Hold	6,300	–	–	0.08%	168
2017 Q1	$689K	Buy	6,300 +800	+15%	+$70.4K	0.08%	198
2016 Q4	$405K	Hold	5,500	–	–	0.06%	249
2016 Q3	$480K	Buy	5,500 +1,300	+31%	+$123K	0.07%	207
2016 Q2	$361K	Hold	4,200	–	–	0.06%	234
2016 Q1	$334K	Sell	4,200 -1,000	-19%	-$90.5K	0.06%	232
2015 Q4	$654K	Hold	5,200	–	–	0.11%	139
2015 Q3	$542K	Hold	5,200	–	–	0.15%	130
2015 Q2	$642K	Hold	5,200	–	–	0.15%	135
2015 Q1	$613K	Hold	5,200	–	–	0.14%	146
2014 Q4	$620K	Hold	5,200	–	–	0.15%	146
2014 Q3	$584K	Hold	5,200	–	–	0.14%	146
2014 Q2	$492K	Hold	5,200	–	–	0.12%	174
2014 Q1	$368K	Hold	5,200	–	–	0.09%	239
2013 Q4	$384K	Hold	5,200	–	–	0.09%	233
2013 Q3	$394K	Hold	5,200	–	–	0.1%	214
2013 Q2	$416K	Buy	+5,200	New	+$383K	0.11%	192

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

SMDAM

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return

E. Ohman J:or Asset Management's VRTX Position: Q2 2026 in Review

E. Ohman J:or Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 8,823 shares worth $4.38M. The position accounts for 0.1% of the portfolio, ranked #106.

E. Ohman J:or Asset Management first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. The position peaked at $37.4M in Q1 2021. 337 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

E. Ohman J:or Asset Management held 8,823 shares of Vertex Pharmaceuticals worth $4.38M as of Q2 2026.
E. Ohman J:or Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.1% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #106 holding.
E. Ohman J:or Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
E. Ohman J:or Asset Management's Vertex Pharmaceuticals position peaked at $37.4M in Q1 2021.
337 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.